Skip to main content
TipRanks
Go Ultimate75% OFF

Orexo AB (C5G) Q3 2026 Earnings Report

0 Followers

DE:C5G Q3 2026 EPS Results

Actual EPS
-EUR 0.15
Consensus EPS
-EUR 0.12
Beat/Miss
Missed by -EUR 0.04
One Year Ago EPS
-EUR 0.05

DE:C5G Q3 2026 Revenue Results

Actual Revenue
EUR 72.03K
Expected Revenue
EUR 405.18K
Beat/Miss
Missed by -EUR 333.14K
YoY Revenue Growth
-99.33%

Earnings Announcement Details

Quarter
Q3 2026
Date
10/22/2026
Time
Before Open
Conference Call
Thursday, October 22, 2026
DE:C5G Upcoming Earnings

Orexo AB's next earnings date is estimated for February 4, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:C5G Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Oct 22, 2026|% Change Since:-85.35%|
Earnings Call Sentiment|Positive

The call had a cautiously positive operational tone, with meaningful progress on Izipry, OX640, OX390, semaglutide, partnerships, and cost restructuring. However, the company continues to face substantial financial pressures, including low revenue, a SEK 118 million loss from continued operations, negative cash flow, reduced own cash of SEK 62 million, large historical Zubsolv-related obligations, and pending regulatory and partnering milestones. The number and importance of development milestones and the planned rights issue outweighed the challenges, supporting an overall positive sentiment.

Company Guidance

Orexo expects Izipry to have a six months of review time, with approval expected in the end of Q1 next year; OX640 is on track to start its pivotal trial in Q4, with results expected in first half of next year, potentially into the beginning of Q2, and the company expects to announce the trial start also in this quarter. Normalized OpEx was SEK 55 million or SEK 18 million per month, but the 18 is higher than where they are aiming, and OpEx is expected to further decline in 2027, with cash flow getting closer to the EBITDA; the ambition is to have a runway taking the company past 2027 without income from partnering. The Zubsolv earn-out is expected in Q1 of next year, BARDA resource contribution is up to $54 million, and the DOJ payment is provisioned at up to $4 million over several years, while no significant numbers are foreseen from Zubsolv rebates moving from now on.

  • Progress in Strategic TransformationOrexo said it made substantial progress toward becoming a platform-focused company, including restructuring its balance sheet and operations, streamlining costs, and focusing on partnerships around the AmorphOX platform.
  • Rights Issue to Support Development ProgramsThe announced rights issue is expected to close during the quarter and is intended to provide the financial flexibility needed to advance critical development milestones and take the company through its transformation.
  • Izipry FDA ResubmissionOrexo resubmitted the Izipry file to the FDA on September 29 and expects a six-month review, with approval anticipated toward the end of the first quarter next year. The company said the majority of development work is complete and that ongoing shelf-life and reliability work will require significantly lower spending.
  • OX640 IND Acceptance and Manufacturing ProgressThe FDA accepted the OX640 IND, confirming the clinical trial program. Orexo also manufactured 12,000 units of OX640 at commercial scale and is conducting final quality testing before release for the clinical trial.
  • OX640 Pivotal Trial on TrackOrexo said it remains on track to start the first pivotal OX640 trial in the fourth quarter. The planned nasal allergen challenge study will test the final product and dose in allergic rhinitis patients, with results expected in the first half of next year, potentially extending into the beginning of the second quarter if additional analysis is required.
  • BARDA Expansion for OX390BARDA agreed to extend the initial OX390 development stage and provide an additional $3 million of overall funding. Orexo also expects to receive reimbursement for OX390-related costs, with SEK 7 million of higher BARDA reimbursement recognized in the quarter and total BARDA support described as up to $54 million.
  • Encouraging Oral Semaglutide ResultsIn its first oral AmorphOX semaglutide formulation study, Orexo achieved bioavailability comparable to the reference tablet after testing only four formulations over a relatively short timeframe. The industry partner is interested in continuing the oral program and exploring additional delivery routes.
  • Expansion Opportunities for Semaglutide and AmorphOXOrexo and its semaglutide partner are evaluating additional delivery pathways, including reconstitution and inhalable products. Management said the discussion is focused on how to continue rather than whether to continue.
  • Vaccine Collaboration and Grant ApplicationsOrexo is collaborating with a well-regarded U.S. research institution to test the AmorphOX platform in vaccine projects and is seeking non-dilutive grant funding. The company has also started application processes in the U.S. for additional vaccine-related funding.
  • Improving Zubsolv Earn-Out OutlookBased on the current trajectory of U.S. Zubsolv sales and increased commercialization efforts by Dexcel, Orexo increased its expected earn-out provision by SEK 21 million. The earn-out is expected in the first quarter next year, with some of the increase also reflecting a stronger dollar.
  • Progress Toward DOJ ResolutionOrexo said it has agreed in principle with the Department of Justice on the main terms of a settlement after approximately six years of effort. The company described resolving the investigation as an important cornerstone of its transformation and said only administrative items remain.
  • Cost Reduction ProgramNormalized operating expenses were SEK 55 million for the quarter, or SEK 18 million per month. Orexo has implemented staff reductions, reduced facility costs, finalized the Izipry development phase, and increased partner contributions and risk sharing, with further cost-efficiency efforts planned.
  • Expected Reduction in Future Cash BurnManagement said approximately 70% of the relatively large Q3 cash outflows were non-recurring, primarily related to the discontinued digital mental health business and DOJ settlement negotiations. Izipry-related spending is expected to decline significantly next year, and Orexo aims to reduce operating expenses and extend its runway beyond 2027 without assuming partnering income.
  • Zubsolv Europe Commercialization ProgressAccord released Zubsolv for sale in Europe after completing its manufacturing setup, and the partner is expanding commercialization into additional European markets. Orexo expects this to support future Zubsolv Europe royalties.
  • Expanded Business Development FocusOrexo hired Raheleh Nassaji as head of business development. Management said she has already generated promising leads and is working to expand partnerships across Izipry, OX640, semaglutide, vaccines, and other AmorphOX-enabled projects.
  • OX640 Product Differentiation and Market OpportunityOrexo cited OX640's potential rapid onset, stability, extensive absorption, and long shelf life, along with patent protection for OX640 and other AmorphOX projects reaching into the 40s. The company also noted improving reimbursement and a price premium for nasal epinephrine products compared with some generic injectables in several markets.
  • Flexible Partner-Funded R&D StrategyOrexo is increasingly using partner-funded R&D, activity-based external expenses, and risk sharing to reduce its own cost and exposure. The company aims for future partnerships to generate milestone payments and royalties when products reach the market.

DE:C5G Earnings History

DE:C5G earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 04, 20272026 (Q4)-0.11--0.07――
Oct 22, 20262026 (Q3)-0.12-0.15-0.05-204.79% (-0.10)
Jul 16, 20262026 (Q2)-0.09-0.12-0.06-91.39% (-0.06)
Apr 28, 20262026 (Q1)―-0.17-0.03-552.43% (-0.14)
Feb 05, 20262025 (Q4)-0.02-0.07-0.1962.10% (+0.12)
Oct 23, 20252025 (Q3)-0.03-0.05-0.0725.59% (+0.02)
Jul 16, 20252025 (Q2)-0.02-0.06-0.06-10.60% (-0.01)
May 06, 20252025 (Q1)-0.07-0.03-0.01-76.69% (-0.01)
Feb 06, 20252024 (Q4)-0.09-0.19-0.03-524.56% (-0.16)
Oct 24, 20242024 (Q3)-0.04-0.07-0.05-24.67% (-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed